Skip to main content
Log in

The role of NAD(P)H: quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells

  • Original Articles
  • Mitomycin C Porfiromycin Quinone Reductase
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A mitomycin C (MMC)- and porfiromycin (PFM)-resistant subline of the HCT 116 human coloncancer cell line was isolated after repeated exposure of HCT 116 cells to increasing concentrations of MMC under aerobic conditions. The MMC-resistant subline (designated HCT 116-R30A) was 5 times more resistant than the parent cells to MMC and PFM under aerobic conditions. Both the MMC-resistant cells and the parent HCT 116 cells accumulated similar amounts of PFM by passive diffusion, but levels of macromolecule-bound PFM were about 50% lower in the resistant cell line, implying a decrease in PFM reductive activation in the resistant cells. The finding that microsomes from either sensitive or resistant cells showed an equal ability to reduce MMC and PFM indicated that the activity of NADPH cytochrome P-450 reductase (EC 1.6.2.4) was not changed in the resistant subline. Soluble extracts of HCT 116 cells reduced MMC and PFM more effectively at pH 6.1, and NADH and NADPH were utilized equally well as electron donors under both aerobic and anaerobic conditions. These data suggest that quinone reductase (EC 1.6.99.2; DT-diaphorase) in soluble extracts is responsible for the reduction of MMC. Quinone reductase activities in soluble extracts of HCT 116-R30A cells for the reduction of dichlorophenol indophenol (DCPIP) and menadione-cytochrome c at optimal pHs were decreased by 95% as compared with those obtained in parent cells. However, the MMC-reducing activity of HCT 116-R30A soluble extracts was only 50% lower than that of the parent cell extracts. The kinetic constants (K m, Vmax) found for quinone reductase in the two cell lines with respect to the substrates DCPIP and menadione differed. Two species of mRNA for quinone reductase (2.7 and 1.2 kb) were detected in both cell lines, and there was no detectable difference between parent and resistant cells in the steady-state level of either of these mRNA species. Furthermore, incubation with the quinone reductase inhibitor dicoumarol rendered HCT 116 cells more resistant to MMC. Alteration of the quinone reductase activity in HCT 116-R30A cells appears to be the mechanism responsible for their resistance to MMC and PFM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

NAD(P)H:

reduced nicotinamide adenosine dinucleotide (phosphate)

MMC:

mitomycin C

PFM:

porfiromycin

PBS:

phosphate-buffered saline

DCPIP:

2,6-dichlorophenol indophenol

DIC:

dicoumarol

c- and t-AHME:

cis- andtrans-7-amino-1-hydroxyl-2-methoxyaminomitosene

EDTA:

ethylenediaminetetraacetic acid

AME:

7-aminio-2-methoxyaminomitosene

DMSO:

dimethylsulfoxide

SSC:

20xSSC contains 3m NaCl and 0.3m sodium citrat

SSPE: 20xSSPE:

contains 3m NaCl, 0.2m monosodium phosphate, and 20mm EDTA

SDS:

sodium dodecyl sulfate

References

  1. Akman AS, Forrest G, Chu FF, Esworthy RS, Doroshow JH (1990) Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res 50: 1397

    Google Scholar 

  2. Begleiter A, Robotham E, Lacey G, Leith MK (1989) Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett 45: 173

    Google Scholar 

  3. Chakrabarty S, Danels YJ, Long BH, Willson JKV, Brattain MG (1986) Circumvention of deficient activation in mitomycin C-resistant human colonic carcinoma cells by the mitomycin C analogue BMY25282. Cancer Res 46: 3456

    Google Scholar 

  4. Chou J, Chou TC (1985) Dose effect analysis with microcomputers. Elsevier, Amsterdam

    Google Scholar 

  5. Crooke ST (1979) Mitomycin C: an overview. In: Carter SK, Crooke ST (eds) Mitomycin C-current status and new developments. Academic Press, New York, p. 1

    Google Scholar 

  6. Doroshow JH (1981) Mitomycin C-enhanced superoxide and hydrogen peroxide formation in rat heart. J Pharmacol Exp Ther 218: 206

    Google Scholar 

  7. Dorr RT, Liddil JD, Trent JM, Dalton WS (1987) Mitomycin C resistant L1210 leukemia cells: association with pleiotropic drug resistance. Biochem Pharmacol 36: 3115

    Google Scholar 

  8. Dulhanty AM, Whitmore GF (1991) Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res 51: 1860

    Google Scholar 

  9. Ernster L (1967) DT diaphorase. Methods Enzymol 10: 309

    Google Scholar 

  10. Forrest GL, Qian J, Ma J, Kaplan WD, Akman S, Doroshow J, Chen S (1990) Rat liver NAD(P)H:quinone reductase: cDNA expression and site-directed mutations. Biochem Biophys Res Commun 169: 1087

    Google Scholar 

  11. Hissin PJ, Hilf R (1978) Characteristics of proline transport into R3230AC mammary tumor cells. Biochim Biophys Acta 508: 401

    Google Scholar 

  12. Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, Harris AL, Hickson ID (1990) Decreased NADPH: cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res 50: 4691

    Google Scholar 

  13. Hodnick WF, Sartorelli AC (1991) Reductive activation of mitomycin C by NADH-cytochrome b reductase. Proc Am Assoc Cancer Res 32: 397

    Google Scholar 

  14. Jaiswal AK, McBride OW, Adesnik M, Nebert DW (1988) Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase cDNA sequence and localization of gene to chromosome 16. J Biol Chem 263: 13572

    Google Scholar 

  15. Kalyanaraman B, Perez-Reyes E, Mason RR (1980) Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta 630: 119

    Google Scholar 

  16. Keyes SR, Rockwell S, Sartorelli AC (1985) Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. Cancer Res 45: 213

    Google Scholar 

  17. Komiyama T, Kikuchi T, Sugiura Y (1982) Generation of hydroxyl radical by anticancer quinone drugs carbazilquinone, mitomycin C, aclacinomycin A and Adriamycin in the presence of NADPH-cytochrome P-450 reductase. Biochem Pharmacol 31: 3651

    Google Scholar 

  18. Lenaz L (1985) Mitomycin C in advanced breast cancer. Cancer Treat Rev 12: 235

    Google Scholar 

  19. Long BH, Willson JKV, Brattain DE, Musial S, Brattain MG (1984) Effects of mitomycin on human colon carcinoma cells. J Natl Cancer Inst 73: 787

    Google Scholar 

  20. Lowry OH (1957) Micromethods for the assay of enzymes. Methods Enzymol 4: 366

    Google Scholar 

  21. MacDonald JS, Schein PS, Woolley PV, Smythe T et al. (1980) 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 9340: 533

    Google Scholar 

  22. Marshall RS, Paterson MC, Rauth AM (1989) Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions. Br J Cancer 59: 341

    Google Scholar 

  23. Moertel CG, Reitemeier RJ, Hahn RG (1968) Mitomycin C therapy in advanced gastrointestinal cancer. JAMA 204: 1045

    Google Scholar 

  24. Musser SM, Pan S, Callery PS (1989) Liquid chromatograph-thermospray mass spectrometry of DNA adducts formed with mitomycin C, profiromycin and thiotepa. J Chromatogr 474: 197

    Google Scholar 

  25. Pan S, Iracki T (1988) Metabolites and DNA-adduct formation from flavoenzyme activated porfiromycin. Mol Pharmacol 34: 223

    Google Scholar 

  26. Pan S, Andrews P, Glover C, Bachur NR (1984) Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 259: 959

    Google Scholar 

  27. Pan S, Johnson R, Gonzelez H, Thohan V (1989) Mechanism of transport and intracellular binding of porfiromycin in HCT 116 human colon carcinoma cells. Cancer Res 49: 5048

    Google Scholar 

  28. Rockwell S, Kallman RF (1973) Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat Res 53: 281

    Google Scholar 

  29. Rockwell S, Keyes SR, Sartorelli AC (1988) Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro. Cancer Res 48: 5471

    Google Scholar 

  30. Rose WC, Huftalen JB, Bradner WT, Schurig E (1986) Characterization of P388 leukemia resistant to mitomycin C (MMC). Proc Am Assoc Cancer Res 27: 260

    Google Scholar 

  31. Sambrook J, Fritsch EF, Maniatis T (1989) Electrophoresis of RNA through gel containing formaldehyde. In: Ford N, Nolan C, Ferguson N (eds) Molecular cloning, a laboratory manual, (2nd edn), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, Vol 1: 7.43

    Google Scholar 

  32. Schlager JJ, Powis G (1988) Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone-acceptor) oxidoreductase. Cancer Chemother Pharmacol 22: 126

    Google Scholar 

  33. Siegel D, Gibson NW, Preusch PC, Ross D (1990) Metabolism of mitomycin C (MC) by DT-diaphorase (DTD): role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483

    Google Scholar 

  34. Siegel D, Gibson NW, Preusch PC, Ross D (1991) pH-Dependent metabolism of mitomycins by DT-diaphorase. Proc Am Assoc Cancer Res 32: 396

    Google Scholar 

  35. Steven CL, Taylor KG, Munk ME, Marshall WS, Noll K, Shal LG, Uzu K (1964) Chemistry and structure of mitomycin C. J Med Chem 8: 1

    Google Scholar 

  36. Tomasz M, Lipman R (1981) Reductive mechanism and alkylating activity of mitomycin C induced by rat liver microsomes. Biochemistry 20: 5056

    Google Scholar 

  37. Wallach DFH, Karmat VB (1966) Preparation of plasma-membrane fragments from mouse ascites tumor cells. Methods Enzymol 8: 164

    Google Scholar 

  38. Wermuth B, Platts KL, Seidel A, Oesch F (1986) Carbonyl reductase provides the enzymatic basis of quinone detoxification in man. Biochem Pharmacol 35: 1277

    Google Scholar 

  39. Willson JKV, Long BH, Marks ME, Brattain DE, Wiley JE, Brattain MG (1984) Mitomycin C resistance in a human colon carcinoma cell line associated with cell surface protein alterations. Cancer Res 44: 5880

    Google Scholar 

  40. Willson JKV, Chakrabarty S, Long BH, Brattain MG (1987) Deficient activation of mitomycin C in naive resistant human colon cancer cells. Proc Am Assoc Cancer Res 23: 286

    Google Scholar 

  41. Workman P, Walton MI, Powis G, Schlager JJ (1989) DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer 60: 800

    Google Scholar 

  42. Yasukochi Y, Masters BSS (1976) Some properties of detergentsolubilized NADPH-cytochrome C (cytochrome P-450) reductase purified by biospectific affinity chromatography. J Biol Chem 251: 5337

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This work was supported by grant CH-412 from the American Cancer Society and by an award from the Bressler Fund of the University of Maryland School of Medicine (to S. P.)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pan, Ss., Akman, S.A., Forrest, G.L. et al. The role of NAD(P)H: quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells. Cancer Chemother. Pharmacol. 31, 23–31 (1992). https://doi.org/10.1007/BF00695990

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00695990

Keywords

Navigation